Current strategies for the treatment of acute myeloid leukemia (AML) focus on the induction of cell death by standard chemotherapy or targeted therapy. In elderly patients with chemorefractory disease the prognosis is still poor and allogeneic hematopoietic stem cell transplantation is rarely feasible. Several retrospective studies have assessed the role of hypomethylating agents 5--azacytidine (AZA) and 2--deoxy--5--azacytidine (decitabine) in this patient group, but response rates were disappointing when compared to first--line treatment. [1] [2] [3] Therefore, novel salvage strategies should be developed focusing on induction of remission and prolongation of survival. The most striking improvement of AML therapy has been achieved in acute promyelocytic leukemia (APL) treated with the retinoic acid receptor (RAR) specific ligand, all--trans retinoic acid (ATRA). RARs belong to the family of ligand--dependent transcription factors that heterodimerize with the retinoid X receptor (RXR analysis was performed in a retrospective manner.
heterodimer with RXR and is a transcriptional key regulator of cell growth, differentiation and apoptosis. 4 In vitro models have demonstrated that natural and synthetic PPARγ ligands (e.g.
pioglitazone, PGZ) suppressed clonogenic growth of AML and their combination with ATRA synergistically induced myeloid cell differentiation. 5, 6 We herein present in a small cohort of five elderly AML patients that a novel biomodulatory therapy with low--dose AZA combined with PGZ, and ATRA (APA) induced complete molecular remissions in primary chemorefractory disease.
Five elderly AML patients were treated after informed consent with AZA, PGZ, and ATRA (APA) on a compassionate--use basis. Treatment was performed in the absence of alternative therapeutic options outside a clinical trial. Four patients were refractory to standard induction and/or high--dose cytarabine treatment (patient 1 to 4) and one patient was progressive from chronic myelomonocytic leukemia (CMML)--2 to AML during standard--dose AZA treatment (patient 5). Patients were not eligible for allogeneic hematopoietic stem--cell transplantation because of age, comorbidities or lack of suitable donors. Patient and disease characteristics are summarized in Table 1 . The treatment consisted of low--dose AZA 75 mg/day given subcutaneously from day 1--7, PGZ 45 mg/day per os, and ATRA 45 mg/m²/day per os. Subsequent cycles of AZA were administered at an interval of 28 days or later after hematologic recovery. PGZ and ATRA were given continuously from day 1 on. Treatment response was frequently monitored and remission was defined according to standard criteria. 7 Data analysis was performed in a retrospective manner.
Patient 1 was a 65--year--old man who started APA treatment after induction failure to daunorubicin/cytarabine (DA) and high--dose cytarabine/mitoxantrone (HAM). He developed complete remission (CR) with residual thrombocytopenia (CRi) and cytogenetic CR (CRc) after first cycle and molecular CR (CRm) after second cycle of therapy. Because of exacerbation of his preexisting schizophrenic disorder, ATRA was discontinued on day 43 (after cycle 2) and hence, further AZA doses were increased to 75 mg/m². The patient remained in CRm at last visit under AZA/PGZ treatment for 7.5 months after start of APA (Table 1) .
Patient 2 was a 64--year--old man with secondary AML and resistance to three different induction therapies (Table 1) . During APA therapy he achieved a rapid and sustained CRc and CRm (MLL--ratio, 0.320 and FLT3--ITD negative after third APA cycle) ( Figure 1A ). At last visit, the patient remained in transfusion--independent CRi (minimum platelets count 50 x 10 9 /L) and CRm for 7 months after start of APA. Counts of white blood cells and neutrophils during APA treatment are depicted in Figure 1B . was initiated which resulted in slight reduction of bone marrow (BM) blasts from 45% to 30% (Table   1 ). After two cycles of APA, morphologic CR with detection of ring sideroblasts was achieved.
However, MLL--PTD ratio in BM did not decline significantly ( Figure 1C ). During APA treatment, morphologic features of granulocytes in peripheral blood were suggestive of in vivo differentiation of AML blasts and therefore, we quantified MLL--PTD ratio from isolated granulocytes during APA.
Granulocytes were isolated from peripheral blood by autofluorescence--based fluorescence activated cell sorting (FACS) and subsequently, MLL--PTD transcripts were quantified by real--time polymerase chain reaction (PCR) from purified RNA. Granulocytic MLL--PTD ratio (243.5) was comparable to the ratios in peripheral blood (183.3) and BM (169.9) collected after first cycle of APA and did not decline significantly after second APA (134.6) ( Figure 1C ). This result suggested that early increasing numbers of granulocytes ( Figure 1B and D) observed during APA treatment included a considerable fraction of differentiation--induced leukemia blasts, which might be similar to the differentiation effect described in APL during ATRA therapy. Interestingly, in patient 4 clinical symptoms of lupus erythematosus improved during APA therapy. (Table 1) .
Compared with conventional myelosuppressive chemotherapy regimens, APA treatment was associated with much lower toxicity and could be easily administered in an out--patient setting. The most common APA--related adverse events were hematologic toxicities grade 1--4 (Table 1) As recently shown, biomodulatory combination therapies are widely applicable in metastatic tumor disease and have the capacity to control metastatic lesions and to induce CRs in single patients. 13 By targeting the physical constituents (rationalizations) of the hallmarks of cancer with 'top--down' approaches, we may bypass (molecular--)genetic heterogeneity in chemorefractory AML. To our knowledge, this is the first report describing the combined use of low--dose AZA, PGZ and ATRA to successfully overcome resistance to induction chemotherapy. The rapid decrease of BM blasts even after first APA cycle as well as clinical effectivity in AZA refractory patients 4 and 5 argues against a mere anti--leukemic effect mediated by low--dose AZA. 15 These promising data with APA combination therapy warrant further investigation in clinical trials including patients with chemorefractory AML or patients not qualifying for allogeneic transplantation.
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